The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Open accessAbstract
ABSTRACT Objective To investigate the humoral and cellular immune response to mRNA COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment. Methods Established patients at NYU Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunization. Healthy subjects served as controls (n=26). IgG antibody responses to the spike protein were analyzed for humoral response. Cellular immune response to SARS-CoV-2 was further analyzed using high-parameter spectral flow cytometry. A second independent, validation cohort of controls (n=182) and patients with IMID (n=31) from Erlangen, Germany were also analyzed for humoral immune response. Results Although healthy subjects (n=208) and IMID patients on biologic treatments (mostly on TNF blockers, n=37) demonstrate robust antibody responses (over 90%), those patients with IMID on background methotrexate (n=45) achieve an adequate response in only 62.2% of cases. Similarly, IMID patients do not demonstrate an increase in CD8+ T cell activation after vaccination. Conclusions In two independent cohorts of IMID patients, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunization efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines. KEY MESSAGES What is already known about this subject? The impact of COVID-19 has been felt across the globe and new hope has arisen with the approval of mRNA vaccines against the SARS-CoV-2. Studies have shown immunogenicity and efficacy rates of over 90% in the immunocompetent adult population. However, there is a lack of knowledge surrounding the response of patients with immune-mediated inflammatory diseases (IMIDs) who may also be on immunomodulatory medications. Patients with IMID have been shown to have attenuated immune responses to seasonal influenza vaccination. What does this study add? This study looks at the humoral and cellular immune response to two doses of BNT162b2 mRNA COVID-19 Vaccine in participants with IMID (on immunomodulators) compared with healthy controls. Individuals with IMID on methotrexate demonstrate up to a 62% reduced rate of adequate immunogenicity to the BNT162b2 mRNA vaccination. Those on anti-cytokine or non-methotrexate oral medications demonstrate similar levels of immunogenicity as healthy controls (greater than 90%). Similarly, vaccination did not induce an activated CD8+ T cell response in participants on background methotrexate, unlike healthy controls and patients with IMID not receiving methotrexate. How might this impact of clinical practice or future developments? These results suggest that patients on methotrexate may need alternate vaccination strategies such as additional doses of vaccine, dose modification of methotrexate, or even a temporary discontinuation of this drug. Further studies will be required to explore the effect of these approaches on mRNA vaccine immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×
“While immunosenescence may reduce the level of antibody responses to immunizations,(20) recent studies on COVID-19 mRNA vaccines have not shown differences in clinical outcomes for the older population.(6) In our study, IMID patients on methotrexate were generally older which may potentially explain some differences i…”
BackgroundAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationA serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068
Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
Haberman, R., Axelrad, J., Chen, A., Castillo, R., Yan, D., Izmirly, P., Neimann, A., Adhikari, S., Hudesman, D., & Scher, J. U. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2009567 · Cited by 405
Self-citationGeisen, U. M., Berner, D. K., Tran, F., Sümbül, M., Vullriede, L., Ciripoi, M., Reid, H. M., Schaffarzyk, A., Longardt, A. C., Franzenburg, J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220272 · Cited by 355
Hua, C., Barnetche, T., Combe, B., & Morel, J. (2014) · Arthritis Care & Research · doi:10.1002/acr.22246 · Cited by 287
Park, J. K., Lee, Y. J., Shin, K., Ha, Y.-J., Lee, E. Y., Song, Y. W., Choi, Y., Winthrop, K. L., & Lee, E. B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213222 · Cited by 217
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
Kalimuddin, S., Tham, C. Y. L., Qui, M., de Alwis, R., Sim, J. X. Y., Lim, J. M. E., Tan, H.-C., Syenina, A., Zhang, S. L., Le Bert, N., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.003 · Cited by 188
Cited by
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Levin, M. J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., Levinson, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116620 · Cited by 662
M1/M2 macrophages and their overlaps – myth or reality?
Strizova, Z., Benesova, I., Bartolini, R., Novysedlak, R., Cecrdlova, E., Foley, L. K., & Striz, I. (2023) · Clinical Science · doi:10.1042/cs20220531 · Cited by 612
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 507
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee, A. R. Y. B., Wong, S. Y., Chai, L. Y. A., Lee, S. C., Lee, M. X., Muthiah, M. D., Tay, S. H., Teo, C. B., Tan, B. K. J., Chan, Y. H., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068632 · Cited by 498
Deepak, P., Kim, W., Paley, M. A., Yang, M., Carvidi, A. B., Demissie, E. G., El-Qunni, A. A., Haile, A., Huang, K., Kinnett, B., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1757 · Cited by 418
Metadata
- Authors
- Haberman, R. H., Herati, R., Simon, D., Samanovic, M., Blank, R. B., Tuen, M., Koralov, S. B., Atreya, R., Tascilar, K., Allen, J. R., Castillo, R., Cornelius, A. R., Rackoff, P., Solomon, G., Adhikari, S., Azar, N., Rosenthal, P., Izmirly, P., Samuels, J., Golden, B., Reddy, S. M., Neurath, M. F., Abramson, S. B., Schett, G., Mulligan, M. J., & Scher, J. U.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 80
- Issue
- 10
- Pages
- 1339-1344
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W3164513520
- Cited by
- 272
- References
- 22
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. https://app.cochat.ai/papers/10.1136/annrheumdis-2021-220597
- The paper
- Haberman, R. H., Herati, R., Simon, D., Samanovic, M., Blank, R. B., Tuen, M., Koralov, S. B., Atreya, R., Tascilar, K., Allen, J. R., Castillo, R., Cornelius, A. R., Rackoff, P., Solomon, G., Adhikari, S., Azar, N., Rosenthal, P., Izmirly, P., Samuels, J., . . . Scher, J. U. (2021). Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-220597
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.